UK biotech un­veils ear­ly da­ta for an­tibi­ot­ic in chron­ic back pain

Per­si­ca Phar­ma­ceu­ti­cals said it has promis­ing Phase 1b re­sults that sup­port its ap­proach of us­ing a two-dose an­tibi­ot­ic to treat a sub­set of pa­tients with …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER